Clinical Trials Browser

Phase 1/2 × Unknown × Carcinoma, Merkel Cell × Clear all

NCT03787602 2023-03-02

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Phase 1/2 Unknown

Carcinoma, Merkel Cell